Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial
Source: Streetwise Reports  (8/17/20)
Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2. More >

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20
Source: Streetwise Reports  (8/14/20)
One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test. More >

Mesoblast Shares Rocket Higher as FDA Committee Votes in Favor of Remestemcel-L for Pediatric SR-aGVHD Patients
Source: Streetwise Reports  (8/14/20)
Shares of Mesoblast Ltd. traded 50% higher after the company reported that the U.S. FDA's Oncologic Drugs Advisory Committee voted nine to one in favor of remestemcel-L (RYONCILâ„¢) for efficacy in children with steroid-refractory acute graft versus host disease. More >

Life Sciences Firm Signs MOU for Phase 3 COVID-19 Study
Source: Streetwise Reports  (8/14/20)
Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19. More >

Biotech Develops Oral Film Strips for Psychedelic Medicine Delivery
Source: Streetwise Reports  (8/12/20)
This development is a technical milestone for Revive Therapeutics and its drug delivery technology. More >

Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia
Source: Streetwise Reports  (8/11/20)
Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea. More >

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial
Source: Streetwise Reports  (8/10/20)
Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection. More >

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space?
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (8/10/20)
Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile. More >

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial
Source: Streetwise Reports  (8/8/20)
Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. More >

Biopharma Preparing to Initiate Phase 3 COVID-19 Trial
Source: Streetwise Reports  (8/7/20)
Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September." More >

Denali Shares Rise 37% on Advancement of DNL151 into Late Stage Parkinson's Trials
Source: Streetwise Reports  (8/6/20)
Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen. More >

Biopharma Gets FDA Approval for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (8/4/20)
Revive Therapeutics' trial will test Bucillamine in patients with mild to moderate COVID-19. More >

Ten Good Reasons to Invest Now Pre-Market in Acurx Pharmaceuticals
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (8/3/20)
Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years. More >

Kodak Shares Triple in a Flash on $765 Million Loan from DFC for New Pharmaceutical Unit
Source: Streetwise Reports  (7/28/20)
Eastman Kodak shares traded more than 200% higher after the company reported it is forming a new business unit to produce essential pharmaceutical components funded by the U.S. International Development Finance Corporation. More >

TCR2 Therapeutics Reports Positive Results in Mesothelin-Expressing Solid Tumor Study
Source: Streetwise Reports  (7/27/20)
Shares of TCR2 Therapeutics traded 30% higher after the firm released encouraging results from the Phase 1 portion of its clinical study of TC-210 in treating advanced mesothelin-expressing solid tumors.

More >

Milestone Shares More than Double After Presenting Updated Clinical Plan for Heart Condition
Source: Streetwise Reports  (7/23/20)
Shares of Milestone Pharmaceuticals traded 150% higher after the company reported regulatory guidance and updated its clinical development plan for etripamil nasal spray designed for self-administered use in PSVT treatment. More >

Biopharma's Therapeutic Jumps to Phase 2 Testing for COVID-19 'to Shut Down the Cytokine Storm'
Source: Streetwise Reports  (7/22/20)
A development update on Sorrento Therapeutics' three coronavirus-related products is provided in a Dawson James report. More >

Dynavax Shares Rise 20% on Partnership with Mount Sinai to Develop Universal Flu Vaccine
Source: Streetwise Reports  (7/17/20)
Shares of Dynavax Technologies reached a new 52-week high after the company reported that it is collaborating with Mount Sinai to develop a universal influenza vaccine candidate with CpG 1018 adjuvant. More >

AC Immune Shares Rise 19% as Firm Advances Alzheimer's Vaccine in Phase 1b/2a Trial
Source: Streetwise Reports  (7/16/20)
AC Immune SA shares set a new 52-week high after the Swiss biotech firm reported that interim data from its Phase 1b/2a phospho-Tau Alzheimer's Vaccine study reconfirms promising safety and Tau-specific immunogenicity observed in the prior clinical trial. More >

Taiwan Liposome Shares Rise 60% on Inhalable Liposomal HCQ Potential Covid-19 Treatment Claims
Source: Streetwise Reports  (7/15/20)
Shares of Taiwan Liposome Co. reached a new 52-week high after the company released a manuscript describing how its inhalable liposomal hydroxychloroquine may provide clinical benefit and offer a potential treatment for Covid-19. More >

Potential Covid-19 Treatment Is Ready for Prime Time
Source: Streetwise Reports  (7/14/20)
Small-cap Algernon Pharmaceuticals is about to begin a multinational Phase 2b/3 trial for Ifenprodil, a repurposed drug with a known safety record. More >

INmune Bio Shares Double after Reporting Positive Phase 1b Alzheimer's Trial Data
Source: Streetwise Reports  (7/14/20)
Shares of INmune Bio reached a new 52-week high after the company reported interim data from its Phase 1b study of XPro1595 that demonstrated decreased neuroinflammation in Alzheimer's patients. More >

BioNTech Shares Rise as FDA Grants It and Partner Pfizer Fast Track Status for Two Covid-19 Vaccine Candidates
Source: Streetwise Reports  (7/13/20)
Shares of BioNTech SE traded 15% higher after the company reported that, together with its partner Pfizer, it has received FDA Fast Track designation for two separate mRNA-based vaccine candidates against SARS-CoV-2. More >

Threat Detection Company Forms Partnership to Advance Covid-19 Pathogen Screening
Source: Streetwise Reports  (7/12/20)
Patriot One Technologies reported it is collaborating with ecoMine Technologies to advance pathogen screening applications as part of Canada's Digital Technology Supercluster's Covid-19 program. More >

Altimmune Shares Up 20% Upon Forming Partnership for Intranasal COVID-19 Vaccine
Source: Streetwise Reports  (7/9/20)
Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVIDâ„¢, its COVID-19 vaccine candidate. More >